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Proper expression of the transcription factor, Positive regulatory domain 1 (PRDM1),
is required for maintaining homeostasis of human monocyte derived-dendritic cells
(MO-DCs). The molecular mechanisms and gene targets of PRDM1 in B and T
lymphocytes have been identified. However, the function of PRDM1 in dendritic cells
(DCs) remains unclear. We investigate co-regulators of PRDM1 in MO-DCs identified
by mass spectrometry (MS) and co-immunoprecipitation (Co-IP). Notably, non-POU
domain-containing octamer-binding protein (NonO) was found to be a PRDM1 binding
protein in the nucleus of MO-DCs. NonO is recruited to the PRDM1 binding site in the
promoter region of IL-6. Knockdown of NonO expression by siRNA lessened suppression
of IL-6 promoter activity by PRMD1 following LPS stimulation. While NonO binding to
PRDM1 was observed in human myeloma cell lines, an effect of NonO on IL-6 expression
was not observed. Thus, loss of NonO interrupted the inhibitory effect of PRDM1 on IL-6
expression in MO-DCs, but not plasma cells. Moreover, MO-DCs with low expression of
PRDM1 or NonO induce an increased number of IL-21-producing TFH -like cells in vitro.
These data suggest that low level of PRDM1 and NonO lead to enhanced activation
of MO-DCs and the regulation of MO-DC function by PRDM1 is mediated through cell
lineage-specific mechanisms.
Keywords: PRDM1, NonO, IL-6, inflammation, dendritic cells

INTRODUCTION
Positive regulatory domain 1 (PRDM1, also named BLIMP1) was identified as a repressor of
interferon beta (IFN-β) gene expression in humans and mice (1, 2). PRDM1 is expressed in
multiple cell lineages and is critical for early development (2–4). The immunological function
of PRDM1 was first identified in B lymphocytes. Expression of PRDM1 is strongly induced in
post-germinal center B cells committed to plasma cell (PC) differentiation (5, 6). In PCs, PRDM1
acts as a master transcription factor through positive regulation of genes involved in plasmablast
(PB) and PC function, and the absence of PRDM1 in B cells in mice leads to a lack of PC with
hypoimmunoglobulinemia despite normal B cell memory responses (7–9).
Genome-wide association studies (GWAS) have identified polymorphisms in PRDM1 that are
associated with autoimmune diseases. Single nucleotide polymorphisms (SNPs) predisposing to
systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are located in the intergenic
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CD14 positive selection kit II (StemCell Technologies) according
to the manufacturer’s protocol. CD14+ monocytes were cultured
with RPMI1640 supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 1% penicillin-streptomycin (P/S), 1%
L-glutamine, 100 ng/ml of recombinant human granulocytemacrophage colony-stimulating factor (GM-CSF) (PeproTech),
and 50 ng/ml of recombinant human IL-4 (PeproTech) for 7
days. Cultures were kept at 37◦ C in a humidified atmosphere
and 5% CO2 . On day 7, MO-DCs were collected only from the
non-adherent cells and the purity of MO-DCs was confirmed
by flow cytometry with antibodies which were purchased from
eBioscience (anti-HLA-DR-FITC: LN3 and anti-CD209-PE/Cy7:
eB-h209) (23). Over 85% of HLA-DR+CD209+ MO-DCs were
obtained consistently. We excluded adherent cells since cells
shows mixed population with CD209+ and CD209- with various
degrees (Figure S1A).

region between PRDM1 and ATG5 (10). Monocyte deriveddendritic cells (MO-DCs), but not B cells derived from healthy
female individuals with the rs548234 SNP, which is a risk factor
for SLE, show a lower level of PRDM1 expression, suggesting
that a proper expression of PRDM1 in dendritic cells (DCs)
is required for immunological homeostasis in a gender-specific
manner (11).
Immunoregulatory functions of PRDM1 in myeloid cells have
been reported; mice with a DC-specific knockout of Prdm1
(Prdm1 CKO) spontaneously develop a lupus-like phenotype
(11). Increased expression of the proinflammatory cytokine
Interleukin-6 (IL-6) in DCs of Prdm1 CKO mice, following
Toll-like receptor (TLR) 4 stimulation, leads to an enhanced
differentiation of follicular helper T cells (TFH ), revealing a
potential pathogenic mechanism for PRDM1 in autoimmune
diseases (11). PRDM1 also participates in the process of antigen
processing and presentation, and regulates expression of class
II trans-activator (CIITA) in PCs and lymphocytes (12, 13),
and cathepsin S (CTSS) in DCs (14). CTSS was higher in
PRDM1-deficient DCs than in control DCs and increased
CTSS activity contributes to development of autoantibodies and
enhanced induction of TFH cells in female Pdrm1 CKO mice
(14). In addition, PRDM1 was identified as a critical downstream
regulator of the aryl hydrocarbon receptor (AHR) during
MO-DC differentiation; a lack of AHR expression enhances
monocytes to macrophages differentiation (15). These studies
together suggest that PRDM1 mediates different regulatory
functions in myeloid cells.
Studies in cell lines suggest that recruitment of chromatin
regulators is important for the suppressive function of PRDM1
(16–19). Studies performed in primary lymphocytes showed that
PRDM1 recruits cell-type specific co-factors in CD4+ T cells,
CD8+ T cells, and in plasmablasts (20–22). While there are some
common target genes among lymphocytes, the majority is cell
type-dependent. These observations suggest that co-factors of
PRDM1 are one of important contributor to cell-type dependent
regulatory mechanisms of PRDM1. In this study, we identified
co-factors of PRDM1 in MO-DCs by immunoprecipitation and
mass spectrometry (IP-MS). Among the candidate proteins, a
non-POU domain-containing octamer-binding protein (NonO,
also named p54nrb) helps PRDM1 to suppress IL-6 expression
by direct binding to the IL6 promoter. Moreover, a deficiency
of PRDM1 or NonO in MO-DCs increases differentiation of IL21 producing TFH -like cells. Together, these observations suggest
that PRDM1 and NonO together regulate DC activation.

Cell Lines
The HEK-293 cell line was purchased from ATCC (ATCC
CRL-1573) and maintained in DMEM with 10% FBS, 1% P/S,
and 1% L-glutamine. The human myeloma cell lines U-266,
RPMI-8266 and Daudi (a gift from Dr. Chiorazzi, FIMR, NY)
were maintained in a 5% CO2 atmosphere in RPMI 1640
supplemented with 15% FBS, 1% P/S, and 1% L-glutamine.

Co-IP and Mass Spectroscopy (MS) Assays
Co-IP was performed as described previously (24). Briefly, 2–
5 µg of PRDM1 rabbit mAb (Cat# OAR03181, Aviva Systems
Biology or cat# 9115s, Cell Signaling Technology) or normal
rabbit immunoglobulin G (IgG) (Cat# 2729, Cell Signaling
Technologies) were coupled to protein G or A-magnetic beads
(DynaBead, Thermo Scientific). Anti-flag M2 magnetic beads
(Milipore) were used to pull-down flag tagged RPDM1 in
some experiments. Nuclear protein was extracted from PRDM1
transfected MO-DCs with a NE-PER nuclear and cytoplasmic
extraction reagents kit (Thermo Scientific) and incubated with a
bead-conjugated PRDM1 antibody or control IgG overnight at
4◦ C. The beads were washed and proteins bound by antibody
were eluted by elution buffer and stored at −80◦ C until used for
either immunoblotting or mass spectrometry. Mass spectrometry
was performed, and analyses were done at cold spring harbor
laboratory shared resources as described previously (25).

Immunoblotting
Western blot was performed as described (24). Cell extracts or
eluted proteins were separated by 4–12% Bis-Tris polyacrylamide
gel electrophoresis (PAGE) (Invitrogen). Proteins were
transferred to polyvinyliden difluoride (PVDF) membrane
(GE Amersham, Hybond-C or Millipore, Immobilon-FL) and
blocked for 1 h at room temperature with 5% non-fat dry milk
in TBS-T buffer (20 mM Tris, 150 mM NaCl, 0.1% Tween20,
pH 7.4). The membranes were then incubated with primary
antibodies to HDAC1 (Cat# 5356s, Cell Signaling Technology),
HDAC2 (Cat# 5113s, Cell signaling Technology), PRDM1
(Cat# 9115s), hnRNPM (Cat# SAB1404107, Sigma Aldrich),
TP53BP1 (Cat# 4937s, Cell Signaling Technology), β-Actin (Cat#
ab8226, Abcam), V5 (Cat# MA5-15253, Sigma Aldrich), and

MATERIALS AND METHODS
Preparations of Peripheral Blood
Mononuclear Cells (PBMCs) and MO-DCs
Differentiation
The protocol for study of human blood was approved by
the Institutional Review Board (approval number: 17-0075).
PBMCs were purified from leukopack (NY Blood center)
as described previously (14). To prepare MO-DCs, CD14+
monocytes were isolated from MO-DCs by EasySep Human
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Flag (Cat# F1804, Sigma Aldrich) overnight at 4◦ C. Proteins
bound by antibody were visualized by ECL (Thermo Scientific, #
34580 or Advansta, K-12045) and sapphire biomolecular imager
(Azure Biosystems).

0.5% NP-40, 0.25% Triton X-100), ChIP Lysis Buffer II (10 mM
Tris-HCl, pH 8.0, 200 mM NaCl, 1 mM EDTA, pH 8.0, 0.5 mM
EGTA, pH 8.0), then ChIP Lysis Buffer III (10 mM Tris-HCl, pH
8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% sodium
deoxycholate, 0.5% N-lauroylsarcosine). All three lysis buffers
were supplemented with complete proteinase inhibitor (Roche),
and each lysis was performed for 10 min at 4◦ C with rotation.
After lysis, chromatin was sheared by sonication (7 cycles of 30 s
ON and 60 s OFF by Q500 sonicator) (Fisher), which generated
fragments ranging from 200 to 800 bp. Ten percent Triton X100 was added to sonicated chromatin (nuclear membrane and
lipids were removed by centrifuge). Ten percent of sonicated
chromatin supernatant was saved as input control. Sonicated
chromatin was incubated with 2 µg of antibody-Protein G and
A Dynabeads (Invitrogen) complex overnight at 4◦ C. Unbound
chromatin was removed with RIPA Buffer (50 mM HEPES.KOH,
pH 7.5, 100 mM LiCl, 1 mM EDTA, 1% NP-40, 0.7% Sodium
Deoxycholate), followed by one time washing with 10 mM pH 8.0
Tris elution buffer. Chromatin elution was done by incubation
with elution buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA 1%
SDS) at 70◦ C for 10 min. DNA and chromatin de-crosslinking
was done by incubation at 65◦ C for overnight in elution buffer.
DNA elute was cleaned by PCR purification kit (Qiagen) and
kept at −20◦ C until PCR or library prep for sequencing. To
detect binding to IL6 promoter regions, primer sets that detect
each PRDM1 consensus sequence was used for PCR. The PCR
condition was as followed: 94◦ C for 5 min; 94◦ C for 30 s, 60◦ C
for 30 s, and 72◦ C for 1 min for 40 cycles.

Plasmids and Transient Transfections
Human PRDM1 Tagged ORF Clone PRDM1 (RC217363L1V)
and human small interfering Ribonuclic acid (siRNA) oligo
duplex exogenous (SR300437; PRDM1 and SR321120; NonO)
were purchased from Origene. FLAG-NonO (pCMV-myc-Flagp54), FLAG-TP53BP1 (pcDNA5-FRT/T0-Flag-53BP1), and V5hnRNPM (pT7-V5-SBP-C1-HshnRNPM) expressing plasmids
were purchased from Addgene. Transfections were prepared
as described in previous study (24). For transient transfection
to HEK-293 cells, 1–2 µg of plasmid was transfected to
70% confluent monolayered HEK-293 cells by Lipofectamin
(Invitrogen). After 24 h, medium was replaced with complete
medium and cells were further cultured for 2 days. 200 nM
siRNA or 1–2 µg of plasmid was transfected to 106 MODCs at day 5 during differentiation by Human Dendritic
Cell NucleofectorTM Kits (Lonza). After transfection, MO-DCs
were further differentiated for 2 days and cells were harvested
for experiments. 106 myeloma cells were transfected by using
NucleofectorTM Kits (R kit for U-266, T kit for RPMI-8226, and
V kit for Daudi) with 400 nM siRNA (Origene), according to
manufacturer’s instructions.

Proximity Ligation Assay (PLA) Assay
The in situ PLA was performed on fixed MO-DCs with Duolink
in situ Detection Reagents Red (Sigma Aldrich) according to
the manufacturer’s instructions. Briefly, cells were fixed with
4% paraformaldehyde (PFA) at room temperature and washed
with PBS. Samples were permeabilized with 0.5% Triton-X-100
in PBS and blocked by blocking solution (provided by the
kit) for 1 h at 37◦ C. Primary antibodies against NonO (Cat#
sc-376865, Santa Cruz), hnRNPM, TP53BP1, PRDM1, V5, Flag
or normal rabbit IgG (Cat# 2729, Cell Signaling Technology)
were incubated overnight at 4◦ C. The samples were washed
twice for 5 min with buffer A (provided by the kit), followed by
incubation with the PLA probes (Sigma Aldrich) for 60 min at
37◦ C. Subsequent ligation for 30 min at 37◦ C and amplification
for 100 min at 37◦ C were performed. Finally, the samples were
mounted using Duolink in situ Mounting Medium with DAPI
(Sigma Aldrich). Z-Stacks Images were captured using a 60X oil
objective on Zeiss Apotome 2 microscope and LSM 880 confocal
microscopy (Carl Zeiss Microscopy). Three-dimensional
foci counting analysis was performed with Imaris software
(Imaris v8.0.2).

Set1: F- 5′ -GCCTCAATGACGACCTAAGC-3′ , R- 5′ -ACGT
CCTTTAGCATGGCAAG-3′ ,
Set2: F- 5′ -GCGATGGAGTCAGAGGAAAC-3′ , R- 5′ -AGCT
GAAGTCATGCACGAAG-3′ ,
Set3: F- 5′ -CCTGGAGACGCCTTGAAGTA-3′ , R- 5′ -CTGT
GAGCGGCTGTTGTAGA-3′ ,
Set4: F- 5′ -TACAGGGAGAGGGAGCGATA-3′ , R- 5′ -GGCA
GAAAGGGGGAGAATAC-3′ ,
Set5: F- 5′ -AAATGCCCAACAGAGGTCAC-3′ , R- 5′ -AAAC
CAGACCCTTGCACAAC-3′ ,
Set6: F- 5′ -CTCCCCCATTTTCATTTTCA-3′ , R- 5′ -TGGG
GAAAGTGAGGTCATC-3′ ,
Set7: F-5′ -TGAACATTTTATCATGAACACGAA-3′ , R- 5′ CGTGCACTGTGATCCGTCTA-3′ ,
Set8: F- 5′ -CGGTGAAGAATGGATGACCT-3′ , R- 5′ -GTGA
CCTCTGTTGGGCATTT-3′ .

Cloning IL-6 Promoter and Luciferase
Reporter Assay
Primers to amplify the IL-6 area (forward, 5’-CGATATAG
CCGAGCTGGAAG-3’; reverse, 5’- AAACCAGACCCTTGCA
CAAC-3’) yield 932-bp amplicon. The PCR condition was as
followed: 94◦ C for 5 min; 94◦ C for 30 s, 60◦ C for 30 s, and
72◦ C for 1 min 15 s for 30 cycles. IL6 PCR product was cloned
in pGL4.25 (Promega). 2 × 104 HEK-293 cells were plated
in 12-well culture plates in DMEM containing 10% FBS and
1% penicillin-streptomycin. IL6 promoter luciferase reporter
construct and tk-Renilla luciferase construct was transfected

Chromatin Immunoprecipitation (ChIP) and
PCR
ChIP assays were performed as previously described (14). 5
× 106 MO-DCs were cross-linked with 1% formaldehyde for
10 min at room temperature and quenched with 125 mM glycine.
Cells were washed with ice-cold 1X DPBS twice. Cell pellets
were lysed in 300 µl ChIP Lysis Buffer I (50 mM HEPES.KOH,
pH 7.5, 140 mM NaCl, 1 mM EDTA, pH 8.0, 10% Glycerol,
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RESULTS

by Lipofectamine 2000 (Invitrogen). At 48 h post-transfection,
transfected cells were lysed and assayed for both firefly and
Renilla luciferase activity using the Dual-GLO Luciferase Assay
System (Promega). Luciferase activity was measured using a
luminometer (Perkin Elmer Victor3). The relative luciferase
activity was calculated by normalization to the level of
Renilla luciferase.

NonO Is a PRDM1 Binding Protein in
MO-DCs
PRDM1 is known to regulate gene expression by recruitment
of chromatin modifiers, including histone deacetylases
(HDACs), lysine-specific demethylase1 (LSD1), protein arginine
methyltransferase (PRMT5), and euchromatic histone-lysine
N-methyltransferase 2 (EHMT2, also known as G9a) in PCs and
primordial germ cells (16–19). PRDM1 also recruits polycomb
repressive complex 2 (PRC2) by directly binding the enhancer of
zeste homolog 2 (Ezh2) domain of PRC2 in murine plasmablasts
(26). We investigated whether PRDM1 recruits the same
chromatin modifiers in MO-DCs. Binding of HDAC1, HDAC
2, PRMT5 or G9A to PRDM1 was assessed by Co-IP; however,
no significant binding of any of those molecules to PRDM1 in
MO-DCs was found (Figure S1B and data not shown).
To identify binding proteins of PRDM1 in a nonbiased way, relative and absolute quantitation (iTRAQ)
MS was performed on the nuclear fraction of MO-DCs
immunoprecipitated by PRDM1 antibody. Compared to the
fraction immunoprecipitated by control IgG, 39 proteins were
pulled-down specifically by the anti-PRDM1 antibody (cutoff
>1.5-fold) (Table S1). Consistent with the Co-IP data, there
were no HDACs or other known chromatin modifiers identified
by mass spectrometry. Thus, PRDM1 does not recruit detectable
chromatin modifiers for regulation of target gene expression
in MO-DCs.
Among the PRDM1-associated proteins identified by
MS, we chose three molecules, NonO, Tumor Protein P53
Binding Protein 1(TP53BP1), and Heterogeneous Nuclear
Ribonucleoprotein M (hnRNPM), as candidate co-regulators of
PRDM1 due to their known transcriptional regulatory functions.
To verify the interaction between those three proteins and
PRDM1, Co-IP was performed in HEK-293 cells. Since HEK-293
cells do not express PRDM1 endogenously, they were transiently
transfected with vectors encoding PRDM1 and Flag-NonO,
Flag-TP53BP1, or V5-hnRNPM. As expected, PRDM1 were
not detected in input of non-transfected HEK-293 (Figure 1A,
lane 1) and immunoprecipitated proteins from HEK-293 cell
nuclear extract (PRDM1-negative) did not display any of the
three proteins (NonO, TP53BP1, and hnRNPM) by Western
blot (Figure 1A, lane 6). In contrast, anti-FLAG and anti-V5
immunoblotting, which detect Flag-NonO, Flag-TP53BP1, and
V5-hnRNPM, showed an association between PRDM1 and
NonO and hnRNPM in PRDM1-transfected cells (Figure 1A,
lane 8 and 9) but no interaction between PRDM1 and TP53BP1
(Figure 1A, lane10).
PLA was used to verify these interactions in HEK-293 cells.
PLA is an antibody-based detection technique that permits the
assessment of colocalization between two proteins within <
∼40 nm distance in a cell (27, 28). PLA complexes are depicted as
red puncta and each punctum represents an interaction between
PRDM1 and a candidate molecule. PLA-positive red clusters were
not detected in the technical control, which included incubation
with only anti-PRDM1 antibody (Figure 1B, top panel). All
three candidates, NonO, TP53BP1, and hnRNPM led to PLA

TFH Cell in vitro Differentiation
MO-DCs were differentiated and indicated siRNAs were
transfected at day 5 during differentiation. Cells were
further cultured for 2 days. MO-DCs were stimulated with
lipopolysaccharides (LPS) (1.0 µg/ml) for 6 h and washed. Naïve
CD4+ T cells were isolated from PBMCs by using an Easysep
human naïve CD4+ T cell isolation kit (Stemcell technologies).
1.3 × 103 of LPS pre-stimulated MO-DCs or unstimulated
MO-DCs were co-cultured with 4 × 104 naïve CD4+ T cells
for 6 days. NC (negative control) was naïve CD4+ T cell alone
and PC (positive control) was naïve CD4+ T cells with TFH
differentiation cocktails [CD2/3/28 activation beads (Miltenyl
Biotec), IL-6 (50 ng/ml, R&D systems) and IL-12 (20 ng/ml,
R&D systems)]. TFH cells were analyzed by flow cytometry
with a Fortessa (BD Biosciences). Fixable Viability Dye eFluor
506 (FVD, eBioscience) was used to exclude dead cells. For
flow cytometry, antibodies were purchased from BioLegend
(anti-CXCR5-APC: J252D4), eBioscience (anti-PD1-pacific blue:
EH12.2H7 and anti-CD11c-Amcyan: B-ly6), and BD Bioscience
(anti-IL-21-PE: 3A3-N2 and IFN-γ-APC/Cy7: B27).

Quantitative RT-PCR (qRT-PCR)
Total RNA was extracted with Direct-zol RNA Micro Prep (Zymo
Research,CA) and RNA samples were treated with DNase I to
remove genomic Deoxyribonuclic acid (gDNA) contamination.
cDNA was prepared with the iScript cDNA synthesis kit (BioRad). Gene-specific primers were purchased from Taqman
(Life Technologies) and qRT-PCR was performed with a Light
cycler 480 II (Roche). Taqman primers: Hs00153368_m1
(BCL6),
Hs00172187_m1
(POLR2A),
Hs99999902_m1
(RPLP0), Hs00174131_m1 (IL6), Hs00153357_m1 (PRDM1),
Hs00939763_g1 (NonO), Hs00175407_m1 (CTSS). Relative
expression of a gene of interest to housekeeping gene was
calculated by 1Ct or 11Ct.

ELISA
To measure the cytokine secretion, supernatants from the MODCs were collected and the level of IL-6 was measured by
human IL-6 ELISA kit (DuoSet ELISA kit, R&D Systems,
Minnesota, USA). The lower level of detection for the assay
was 4.68 pg/ml.

Statistics
Statistical analysis was calculated and determined by a nonparametric Man-Whitney test in the Prism 6 (Graphpad
software). P < 0.05 were considered significant.
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FIGURE 1 | Binding of PRDM1 and candidate proteins in HEK-293 cells. HEK-293 cells were transfected PRDM1 alone or together with Flag-NonO, Flag-TP53BP1,
or V5-hnRNPM expression vector. Binding between PRDM1 and each candidate proteins was detected by Co-IP and PLA. (A) Nuclear fraction was
immunoprecipitated with anti- PRDM1 antibodies and immunoblotting was performed with anti-PRDM1, Flag-NonO, Flag-TP53BP1, or V5-hnRNPM antibody. A
representative image from two independent experiments is shown. (B) Binding between PRDM1 and candidate proteins was visualized by PLA (red color) and nuclei
were stained with DAPI (blue). Top panel; technical negative control PLA (PRDM1 antibody alone), other panels; detection of PLA (PRDM1 with Flag or V5 Ab). Scale
bar = 10 µm. A representative image from three independent experiments. Co-IP, co-immunoprecipitation (Co-IP); PLA, proximity ligation assay.

positive clusters with PRDM1 (Figure 1B). The signals from
hnRNPM and NonO were predominantly nuclear while signal
from TP53BP1 was detected in the cytoplasm, suggesting that
the interaction of hnRNPM and NonO with PRDM1 may be
involved in regulation of gene expression while an interaction of
TP53BP1 and PRDM1 may regulate pathways in the cytoplasmic

Frontiers in Immunology | www.frontiersin.org

compartment. This observation explains the lack of association
of TP53BP1 and PRDM1 in the Co-IP of nuclear extracts.
We further validated these results in MO-DCs, in which
we did not need to overexpress PRDM1. No PLA signals were
detected in MO-DCs with any single primary antibodies and
normal IgG (Figure 2A, left panel). As expected, PLA signals
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FIGURE 2 | The interaction of NonO and PRDM1 in the nucleus of MO-DCs. Binding of candidate proteins with PRDM1 in primary MO-DCs was measured by PLA.
(A) MO-DCs were incubated with normal rabbit IgG (left column) or with anti-PRDM1 antibodies (right column) together with anti-TP53BP1, anti-hnRNPM, or
anti-NonO antibodies. Their proximal interaction was assessed by PLA and visualized as red dots. Nucleus was stained with DAPI (blue). Each Z-Stacks maximum
intensity projection image is a representative from three independent experiments and captured 60x magnification. Scale bar = 10 µm. (B) Quantification of the PLA
signal on MO-DCs is represented. PLA signals in each nucleus were quantified by Imaris software. In the plot, horizontal bars indicate the mean with SEM and each
dot represents counts of individual nucleus (n = 40–50). Significance determined by unpaired t-test.

showed that the level of the proinflammatory cytokine IL6 was negatively regulated by PRDM1 in DCs in response
to LPS stimulation (11, 14, 29). If NonO is required for
PRDM1-mediated suppression of target gene expression, NonOdeficiency could lead to an increase in the level of IL-6 after LPS
stimulation. We confirmed the binding of PRDM1 and NonO
in MO-DCs after LPS stimulation (Figure 3A). Next, NonO
or PRDM1 targeting siRNA or scrambled control siRNA was
transfected into MO-DCs and the level of IL-6 was measured.
Effective knockdown of NonO, PRDM1 or both was achieved;
about 50% of either NonO or PRDM1 mRNA was present in
NonO, PRDM1 or both NonO and PRDM1-siRNA compared
to control siRNA transfected MO-DCs (Figure 3B). NonO
expression was unchanged in PRDM1-deficient MO-DCs and
PRDM1 expression was unchanged in NonO-deficient MO-DCs.
To investigate whether IL-6 expression is regulated by the level
of NonO, PRDM1 or both, the level of IL-6 was measured
in the basal state and at 6 h after LPS stimulation. The basal
level of IL-6 mRNA and IL-6 protein in the supernatant were
minimal and no change was detected with knock down of
NonO, PRDM1, or both (Figure S3). In contrast, following LPS

were detected between PRDM1 and NonO in the nucleus of
MO-DCs (Figure 2A, the bottom of right panel). There was no
significant signal detected with hnRNPM and TP53BP1 in either
the nucleus or the cytoplasm (Figure 2A, the top and middle
of right panel). Quantitative analysis of the PLA signal between
PRDM1-candidate proteins and negative control-IgG confirmed
specific PLA signals between PRDM1 and NonO (Figure 2B,
right graph).
Additionally, PRDM1 in nuclear extracts coprecipitated with
NonO but not with hnRNPM and TP53BP1 (Figure S2). These
inconsistent results obtained from primary MO-DCs and HEK293 cells are likely due to the overexpression of PRDM1 in
HEK293 cells. The data obtained from MS, Co-IP and PLA
confirmed that NonO is a novel PRDM1 binding protein in the
nucleus of MO-DCs.

NonO Co-regulates Expression of IL-6 in
MO-DCs
Knowing that PRDM1 and NonO interact in the nucleus of
MO-DCs, we further investigated whether NonO participates
in the transcriptional function of PRDM1. Previous data
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FIGURE 3 | NonO-dependent regulation of IL-6 by PRDM1 in MO-DCs. (A) MO-DCs were stimulated with LPS for 6 h and stained with normal rabbit IgG +
anti-NonO antibodies (left column) or with anti-PRDM1 antibodies + anti-NonO antibodies (right column). Their proximal interaction was assessed by PLA and
visualized as red dots. Nucleus was stained with DAPI (blue). Each Z-Stacks maximum intensity projection image is a representative from three independent
experiments and captured 60x magnification. Scale bar = 10 µm. (B) To knock down NonO, PRDM1, and both (NonO and PRDM1) expression, indicated siRNA or
control siRNA was transfected into MO-DCs and NonO and PRDM1 expression level were quantified by qRT-PCR. Bar graph is a mean ± SEM (n = 9). Significance
determined by Man-Whitney test. (C) Indicated siRNA or control siRNA transfected MO-DCs were cultured with or without LPS (1 µg/ml) for 6 h, and total RNA was
purified. Level of IL6 was measured by qRT-PCR and relative induction was calculated by normalization to the level of LPS stimulated control. Supernatant
concentrations of IL-6 obtained from the cultures were measured using enzyme-linked immunosorbent assay (ELISA). Bar graph is a mean ± SEM (n = 9).
Significance determined by Mann Whitney test. (D) Diagram of human IL6 promoter region with indication of putative PRDM1 binding site (black bar #1–#8) and PCR
primers (open arrow). Primer set for IL6 promoter cloning is designated as black arrows. ChIP was performed with anti-NonO antibodies or control IgG from MO-DCs.
(E) PCR result was visualized in agarose gel. Binding of NonO to PRDM1 consensus sequences within the IL6 promoter were assessed by each primer set (indicated
in C). (F) To quantify the binding of NonO to #5 region, qPCR was performed and calculated by the percent of input. The graph is a mean ± SEM (n = 5). Significance
determined by Mann Whitney test.

stimulation, IL-6 induction (both transcripts and protein in the
supernatant) was increased in siRNA-transfected MO-DCs with
NonO, PRDM1, or both compared to control siRNA-transfected
MO-DCs (Figure 3C). There was no synergistic effect observed
in double-knock down MO-DCs, suggesting PRDM1 and NonO
are in a same regulatory pathway. These data demonstrate
that NonO-deficiency and PRDM1-deficiency lead to the upregulation of IL-6 in LPS stimulated MO-DCs.

Frontiers in Immunology | www.frontiersin.org

Previous reports demonstrated that NonO can regulate gene
expression by binding to promoter regions (transcriptional
regulation) or by binding to mRNA (post-transcriptional
regulation) (30–32). Therefore, we investigated the
mechanism of NonO-mediated IL-6 expression in MODCs. First, binding of NonO to PRDM1-binding sites in
the IL6 promoter area was investigated. A search for the
PRDM1 binding motif in the IL6 promoter area revealed
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FIGURE 4 | NonO regulates IL-6 promoter activity. (A) HEK-293 cells were transfected with NonO siRNA or PRDM1 expressing plasmid. The knockdown efficiency of
siRNA and PRDM1 level was verified by immunoblott analysis. β- actin was used as a loading control. Gel image is a representative from two independent
experiments. (B) The IL6 promoter activity under indicated conditions was determined by luciferase reporter gene analysis. pGL4.25 were used as control vectors.
Mean values of relative luciferase unit (RLU; normalized on Renilla luciferase) from three independent experiments. Bar is a mean ± SEM (n = 4). Significance
determined by unpaired t-test.

siRNA or with NonO siRNA. NonO siRNA led to a 30–
60% decrease in NonO protein levels compared to levels
in control siRNA transfected HEK-293 cells (Figure 4A).
As expected, PRDM1 suppressed IL6 promoter activity; this
suppressive effect was abrogated by a decrease in NonO
(Figure 4B). These results demonstrate that NonO functions to
enable transcriptional repressor of the IL6 gene by PRDM1.
There is no significant change in IL6 promoter activity
by NonO deficiency without PRDM1 expression; thus, the
regulatory mechanism of NonO depends on the PRDM1
expression level.

eight potential PRDM1 binding sites which contain the
consensus sequence (A/C)AG(T/C)GAAAG(T/C)(G/T) or
(A/C)AG(T/C)GAAAT(T/C)(G/T) within 2,000 bp upstream
from transcription start site (TSS) (33) (Figure 3D, #1–#8).
We first performed ChIP-PCR using anti-NonO antibody
or control antibody and the binding of NonO to PRDM1
binding sites in the IL6 promoter region was assessed. The
ChIP efficiency was optimized by detection of P4Hα1, a known
target gene of NonO in DNA precipitated with anti-NonO
antibody compared to control IgG (data not shown) (32).
We performed PCR analysis with primer sets at multiple sites
throughout the IL-6 gene; region #5 (−1,247∼–1,378 bp TSS)
was significantly enriched in DNA precipitated with anti-NonO
antibody (Figure 3E). Thus, the #5 region is recognized by
NonO. The percent of input (%IP) was calculated from the
quantitative PCR (qPCR) and 2–5 fold more enrichment was
observed with anti-NonO antibody compared to control IgG
(Figure 3F). To confirm whether PRDM1 can bind to the
same recognition sequence as NONO, we performed ChIP
with anti PRDM1 antibody. We could detect enrichment of
PRDM1-binding to IL-6 promoter at region (#5), but the
difference between control IgG and PRDM1 was not significant
(Figure S4). Taken together, NonO-PRDM1 complexes are
recruited to IL6 promoter region to suppress IL-6 expression
in MO-DCs.
To further investigate whether NonO can regulate the
transcription of IL6, a luciferase reporter assay was performed.
Since ChIP-PCR results showed that NonO/PRDM1 binding
was enriched in the proximal region [−1.3∼–2.2 kb] of the
IL6 gene promoter, we engineered an IL6 promoter-Luc
plasmid (pGL4.25) containing NonO/PRDM1-binding region
of human genomic DNA. To modulate the level of PRDM1
and NonO in the HEK-293 cell line, HEK-293 cells were
transfected with a PRDM1 expressing plasmid with control

Frontiers in Immunology | www.frontiersin.org

NonO-PRDM1 Complexes Regulate the
Generation of TFH -Like Cells
IL-6 production is one of key factors for murine follicular
helper T cell (TFH ) differentiation, and an increased production
of IL-6 in DCs leads to an expansion of TFH in Prdm1
CKO mice (11, 14, 29). To address the function of PRDM1deficiency and NonO-deficiency in DCs on the differentiation
of CD4+ TFH cells, unstimulated or LPS pre-stimulated MODCs were co-cultured with naïve CD4+ T cells. After coculture, surface phenotype and cytokine production by T cells
were investigated by flow cytometry (Figure 5A). After coculture, live CD4+ T cells were identified by exclusion of FVDpositive (dead cells) and CD11c-positive (MO-DCs). There was
no difference in the expansion of T cells, and CXCR5-positive T
cells were not strongly induced in any culture condition (data
not shown). Interestingly, LPS-stimulated PRDM1-deficient or
NonO-deficient MO-DCs induced a higher percent of IL21+CXCR5-PD1+ cells compared to control siRNA-treated
MO-DCs (Figure 5B). NonO-deficient MO-DCs also induced
higher percent of IL-21+CXCR5-PD1+ T cells even in the
absence of LPS stimulation, but this effect was not observed in
PRDM1- or double deficient MO-DCs (Figure 5B). We do not
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FIGURE 5 | PRDM1- or NonO-deficient MO-DCs induce increased TFH differentiation. Allogenic culture of naïve CD4+ T cells and MO-DCs was set up to induce TFH
differentiation. Expression levels of PRDM1 or NONO in MO-DCs were modulated by transfection with siRNAs before co-culture. After 6-days culture, TFH cell
differentiation was measured by IL-21, IFNγ, CXCR5, and PD1 expression by flow cytometry. (A) A representative flow image. (B) Dead cells were excluded using
Fixable Viability Dye eFluor 506, and the percentage of live CD4+ T cells was calculated. TFH -like cells (CXCR5+/PD1+), CXCR5- helper T cells (CXCR5-/PD1+), and
cytokine expressing helper T cells (CXCR5-/PD1+/ IL21+/ IFN-γ-, and CXCR5-/PD1+/IL21+/ IFN-γ+) were calculated and plotted. Co-culture of T cells with LPS
pre-stimulated MO-DCs was indicated with gray filled box and culture with unstipulated MO-DCs was indicated with open box. Negative control is naïve CD4+ T cell
alone and Positive control is naïve CD4+ T cells with CD2/3/28 activation beads IL-6 (50 ng/ml) and IL-12 (20 ng/ml). In the Box-and-Whisker plot, horizontal bars
indicate the median, boxes indicate 25–75th percentile, and the whiskers indicate 10 and 90th percentile. Four independent experiments (n = 9). Significance
determined by Mann Whitney test. (C) BCL6 expression was quantified by qRT-PCR. Relative expression was calculated to the level of housekeeping gene, POLR2A.
In the Box-and-Whisker plot, horizontal bars indicate the median, boxes indicate 25–75th percentile, and the whiskers indicate 10 and 90th percentile. Three
independent experiments (n = 9). Significance determined by Mann Whitney test.

No synergistic effects of PRDM1 and NonO were observed in IL21 producing TFH -like cell differentiation. Increased production
of IL-6 might contribute to this alteration.

know the mechanism, but NonO may regulate other regulatory
molecules which positively regulate T cell differentiation or
survival. We also compared IFN-γ production in T cells, but
none of T cells were IFN-γ-positive (Figure 5B). To confirm
the IL-21-producing T cells are TFH cells, we measured the
induction of B-Cell Lymphoma 6 (BCL6) which is a master
transcription factor of Tfh cells (34). The BCL6 induction was
small and not significantly higher than negative control group,
and there was no difference of BCL6 levels among the groups
(Figure 5C). Therefore, NonO, PRDM1, or PRDM1/ NonO
deficient MO-DCs generate more IL-21 producing TFH -like cells.

Frontiers in Immunology | www.frontiersin.org

NonO-PRDM1 Interaction Does Not
Regulate IL-6 Expression in Myeloma Cells
Since plasma cells express a high level of PRDM1 and secrete
IL-6, we wanted to know whether PRDM1 and NonO regulate
IL-6 in the human myeloma B cell lines, U-266, and RPMI8226 since both cell lines express a high level of PRDM1
and NonO (Figure S5A). Daudi, a non-myeloma B cell line
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FIGURE 6 | NonO binds with PRDM1 but does not regulate IL-6 in myeloma cells. (A) Binding between PRDM1 and NonO in human myeloma cells was visualized by
PLA (red color) and nuclei were stained with DAPI (blue). Left columns are control groups of PLA (anti-NonO and control IgG) and right columns are experimental
groups (anti-NonO and anti-PRDM1). Scale bar = 15 µm. Images were taken at 60x magnification. A representative image from three independent experiments. (B)
PLA signals in each nucleus were quantified by Imaris software (n = 30–40). Significance determined by Mann Whitney test. (C) 48 h NonO or control siRNA post
transfection, cells were cultured with or without LPS (1 µg/ml) for last 6 h and level of IL-6 measured by qRT-PCR. Bar graph is a mean ± SEM (n = 3). Significance
determined by unpaired t-test.

DISCUSSION

with a high level of NonO but not PRDM1, was used as
a negative control. Using the PLA assay, we found a NonO
and PRDM1 interaction in U-266 and RPMI-8226 in nucleus
but not in Daudi (Figures 6A,B). Next, we tested whether
NonO participates in PRDM1-mediated IL-6 production in these
cells. NonO knockdown mediated by siRNA was sufficient to
decrease the NonO expression level in both U-266 and RPMI8226 cells (Figure S5B). In contrast to MO-DCs, there is high
level of endogenous IL-6 expression in myeloma cells which
was not further increased by stimulation with LPS, and no
significant induction of IL-6 when NonO levels were decreased
(Figure 6C). Similarly, PRDM1-deficiency did not increase the
expression level of basal or LPS stimulated IL-6 mRNAs in U-266
(Figure S5B). Hence, in myeloma cells, NonO could be recruited
to a PRDM1 complex but no PRDM1-mediated regulatory effects
on IL-6 expression by NonO-deficiency and PRDM1-deficiency
were observed.

Frontiers in Immunology | www.frontiersin.org

PRDM1 is a transcription factor that is expressed in multiple
immune cells including myeloid cells (22, 35, 36). A proper
expression is required for terminal differentiation of myeloid
lineage cells (36). It is also involved in immune homeostasis and
an insufficient level of PRDM1 in DCs leads to a breakdown
in immune tolerance in mice (11). However, little is known
about the molecular mechanisms behind its function in myeloid
cells. Previous reports suggest that the suppressive function
of PRDM1 depends on its cofactors. In order to identify
cofactors of PRDM1 in MO-DCs, we performed both Co-IP
and MS experiments. Binding of putative cofactors to PRDM1
was assessed by PLA. These results show that a PRDM1NonO interaction occurs which is localized to the nucleus. The
interaction can be observed even after LPS stimulation. Together,
these molecules regulate IL-6 expression. The regulatory function

10

July 2020 | Volume 11 | Article 1436

Lee et al.

NonO Is a Novel Co-factor of PRDM1

In summary, our data demonstrated that NonO is a co-factor
of PRDM1 and recruitment of NonO by PRDM1 is required
for transcriptional regulatory function of PRDM1 in MO-DCs.
The absence of PRDM1 or NonO increased the expression of
IL-6 which is a positive regulator of IL-21-producing TFH like cell differentiation. NonO interaction to PRDM1 regulates
gene transcription in MO-DCs but not in myeloma cells,
representing a new paradigm for exploring lineage specific effects
of transcriptional regulators.

on IL-6 is observed only in MO-DCs but not in human
myeloma cells. It is well-accepted that IL-6 positively regulates
IL-21 production in T cells, and the activation of STAT3
which is downstream of IL-6R signaling pathway is required
for transcriptional activation of IL-21 (37–39). Deficiency of
either NonO or PRDM1 in MO-DCs also leads to an expansion
of IL-21-producing TFH -like cells in vitro, suggesting that a
proper expression of both NonO and PRDM1 is required for
the proinflammatory function of MO-DCs. Interestingly, NonO
might regulate function of MO-DCs which induces helper T cell
differentiation without LPS stimulation. This alteration is not by
IL-6 expression. Indeed, NonO itself can regulate gene expression
in multiple mechanisms, including chromatin remodeling,
transcriptional regulation, or post-transcriptional regulation (30,
40). We do not know what molecules are targeted by NonO
in MO-DCs under homeostatic condition, and this needs to
be investigated.
It has been previously shown by us and others that allele
specific effects on gene expression may be cell lineage specific.
This has been noted to relate to polymorphism-generated
acquisition or loss of transcription factor binding sites. Indeed, a
PRDM1 SNP that is associated with increased risk for developing
SLE is operative in myeloid cells. The risk allele has a KLF4
binding site, which leads to decreased gene expression. As B
cells do not express KLF4, there is no allele-specific change in
expression of PRDM1 in B cells (23). Here we show differential
effects of transcription factors in myeloid cell and B cells, even
when both lineages express the transcription factors and the
target gene. The mechanism for this requires elucidation. This
could result from different chromatin accessibility of target genes,
from multi-protein complexes including other unidentified
transcription factors or from inhibitors of transcription factor
binding to some regulatory regions of the target gene. In our case,
the difference is not due to the accessibility of a PRDM1-NonO
complex to the genomic area since both cells readily express
IL-6. The functional difference may depend on additional cell
type-specific co-regulators in myeloid cells and B cells. Indeed,
NonO is known to be present in multi-protein complexes in
the nucleus. In an in vitro system, PU.1 (Spi-1) binds to NonO
and impedes NonO binding to RNA (41); the same may relate
to DNA binding although it was not studied in that report.
PU.1 is highly expressed in myeloid cells and in early stage of
B cells, but its expression is suppressed in plasma cells (42)
and completely negative in myeloma cells (43). Therefore, PU.1
might be a candidate regulator in regulation of function of
PRDM1/NonO complex.
Additional remaining questions are what genes other than
IL-6 are regulated by PRDM1 in conjunction with NonO and
what genes are regulated by PRDM1 independent of NonO.
CTSS is another gene which is negatively regulated by PRDM1 in
MO-DCs (14), but CTSS expression was not changed by knock
down of NonO (Figure S6). This suggests PRDM1 regulates gene
expression in both a NonO-dependent and NonO-independent
manner in the same cell, with CTSS as one example of NonOindependent regulation of PRDM1. All of these questions are
critical for understanding the mechanism of gene regulation by
PRDM1 and function in MO-DCs.

Frontiers in Immunology | www.frontiersin.org
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Figure S1 | (A) A representative flow image of MO-DCs. Day 7 of MO-DCs
(non-adherent cells) and adherent cells were collected and viability and the purity
were investigated by exclusion of live/dead fixable marker, FVD and HLA-DR and
CD209 antibodies. Purity of MO-DC was calculated by percentage of live
HLA-DR/CD209 double positivity. (B) Assessment of HDAC binding to PRDM1 by
Co-IP. Nuclear fraction of MO-DCs was immunoprecipitated with anti- PRDM1
antibodies or control IgG and immunoblotting was performed with anti-HDAC1 or
anti-HDAC2 antibodies. A representative image from two independent
experiments is shown.
Figure S2 | Binding of PRDM1 with NonO, hnRNPM, and TP53BP1 by Co-IP.
Nuclear fraction of MO-DCs were incubated with ant-PRDM1 or control IgG and
immunoblotting was performed with anti-NonO, hnRNPM, or TP53BP1
antibodies. Input is an unfractionated total nuclear extract. A representative image
of two independent experiments.
Figure S3 | The basal level of IL-6 transcript and protein were measured by
qRT-PCR and ELISA. NonO, PRDM1, and both (NonO and PRDM1) siRNA or
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knock down the PRDM1 expression, anti-PRDM1 siRNA, or control siRNA was
transfected to U266 cells and PRDM1 level was measured by qRT-PCR. U266
cells transfected with control or anti-PRDM1 siRNA was cultured with or without
LPS (40 µg/ml) for 6 h. Relative level of PRDM1, IL6 was normalized to the level of
POLR2A. Each dot represents an individual sample and the bar is the mean ±
SEM. Significance determined by Mann Whitney test.

control siRNA transfected MO-DCs were cultured without LPS (1 µg/ml) for 6 h,
and total RNA was purified. Relative level of IL-6 was measured by qRT-PCR and
normalized to the level of housekeeping gene, POLR2A. Supernatant
concentrations of IL-6 obtained from the cultures were measured using ELISA. Bar
graph is a mean ± SEM (n = 9). Significance determined by Mann Whitney test.
Figure S4 | Assessment of PRDM1 binding to IL6 promoter regions by
ChIP-qPCR. To test PRDM1 binding to IL6 promoter, ChIP was performed.
Nuclear fraction of MO-DCs and ChIP was performed by anti-RPDM1 or control
IgG as described in material and method. PCR (A) or qPCR (B) was performed to
assess binding of PRDM1 by primers described in material methods. #1–#8
indicates each region including putative PRDM1 binding sites in IL6 promoter. (A)
is a representative image of three independent experiments. (B) To quantify the
binding of PRDM1 to #5 region, qPCR was performed and calculated by the
percent of input. Each dot represents an individual sample and the bar represents
the mean ±SEM (n = 3). Significance determined by Mann Whitney test.

Figure S6 | The level of CTSS was measured by qRT-PCR. NonO, PRDM1, and
both (NonO and PRDM1) siRNA or control siRNA transfected MO-DCs were
cultured with or without LPS (1 µg/ml) for 6 h, and total RNA was purified. Relative
level of CTSS was measured by qRT-PCR and normalized to the level of
housekeeping gene, RPLP0. Then, relative induction was calculated by
normalization to the level of control. Bar graph is a mean ± SEM (n = 6).
Significance determined by Mann Whitney test.
Table S1 | Mass spectrometric identification of candidate PRDM1 binding
proteins in MO-DCs. The comparative analysis of peptide and protein
quantification in normal IgG and PRDM1 of PRDM1-sufficient MO-DCs are
subjected through iTRAQ-based quantitative proteomics with cutoff >1.5-fold.
The experiment was repeated two times. iTRAQ, isobaric tags for relative and
absolute quantitation; MO-DCs, monocyte derived-dendritic cells.

Figure S5 | Expression of IL6 by NonO or PRDM1 in myeloma cells. (A) NonO
expression was knock down by transfection of anti-NonO siRNA or scrambled
control siRNA. After transfection, relative level of NonO was measured by
qRT-PCR and normalized to the level of housekeeping gene, POLR2A. (B) To
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